



## Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium

April 11, 2023 12:30 PM EDT

### Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancers

FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- [Apollomics Inc.](#) (Nasdaq: [APLM](#)), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the company's Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23<sup>rd</sup> Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023.

Dr. Redkar will deliver the presentation, titled, "The HGF/cMet Pathway in Cancer – Early Development to Clinical Evidence," at 11 a.m. PST at the UC Davis Conference Center. Following the event, a copy of the presentation will be made available on the Apollomics website [here](#).

In cancer cells, aberrant HGF/c-Met axis activation, which is closely related to c-Met (or "cMET") gene mutations, overexpression and amplification, promotes tumor growth and proliferation. HGF/c-Met axis also plays an important role in a cancer cell's ability to develop resistance to certain targeted therapies that affect other signaling pathways. Therefore, c-Met and its associated signaling pathways are potentially clinically important therapeutic targets. Apollomics is developing a small molecule, orally bioavailable and highly specific c-Met inhibitor, APL-101, for the treatment of non-small cell lung cancer (NSCLC) and brain tumors.

Dr. Redkar will be joined by other distinguished speakers, including:

- **Paula T. Hammond, Ph.D.:** David H. Koch Chair Professor in Engineering and the Head of the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT)
- **David R. Liu, Ph.D.:** Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT. He is also the founder or co-founder of multiple therapeutics and biotechnology companies, including Chroma Medicine, Exo Therapeutics, Pairwise Plants, Editas Medicine, Beam Therapeutics, Resonance Medicine, Nvelop Therapeutics and Prime Medicine.

The full list of speakers and schedule of the 2023 Miller Symposium can be found here: [R. Bryan Miller Symposium | Chemistry \(ucdavis.edu\)](#)

### About [Apollomics Inc.](#)

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics' lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China.

### Cautionary Statement Regarding Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding the Company's future financial performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics' intellectual property; (v) breaches in data security; (vi) risks related to the ongoing COVID-19 pandemic and response; (vii) the risk that Apollomics may not be able to develop and maintain effective internal controls; (viii) unfavorable changes to the regulatory environment; and those risks and uncertainties discussed in the Form F-4 (as amended) filed by Apollomics, Inc. with the U.S. Securities and Exchange Commission ("SEC") under the heading "Risk Factors" and the other documents filed, or to be filed, by the Company with the SEC. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. Should one or more of the risks or uncertainties described in this press release materialize or should

underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. New risk factors that may affect actual results or outcomes emerge from time to time and it is not possible to predict all such risk factors, nor can Apollomics assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at [www.sec.gov](http://www.sec.gov). Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If Apollomics updates one or more forward-looking statements, no inference should be drawn that Apollomics will make additional updates with respect to those or other forward-looking statements.

## **CONTACTS**

### **Investor Relations**

Peter Vozzo

ICR Westwicke

[Peter.Vozzo@westwicke.com](mailto:Peter.Vozzo@westwicke.com)

+1-443-213-0505

### **Media Relations**

Sean Leous

ICR Westwicke

[Sean.Leous@westwicke.com](mailto:Sean.Leous@westwicke.com)

+1-646-866-4012